Skip to main content
Publications
Morris MJ, de Bono J, Nagarajah J, Sartor O, Wei XX, Nordquist LT, Koshkin VS, Chi KN, Krause BJ, Herrmann K, Rahbar K, Vickers A, Mirante O, Ghouse R, Fizazi K, Tagawa ST. Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: analysis of the phase 3 VISION trial. Cancer. 2024 Oct 15;130(20):3426-35. doi: 10.1002/cncr.35438
Hoffman E, Mladsi DM, Cryer B, Hopkins W, Brater DC, Parikh R, Goyal R, Castellsague J, Stafkey-Mailey D, Young C. Dose-related risks of cardiovascular, gastrointestinal, and renal adverse events associated with meloxicam among patients with osteoarthritis: an observational study using US claims data. Poster presented at the 2016 ACR/ARHP Annual Meeting; November 15, 2016. Washington, DC. [abstract] Arthritis Rheumatol. 2016 Sep 28; 68(Suppl 10).
Gossec L, Kvien TK, Conaghan PG, Ostergaard M, Canete JD, Gaillez C, Mpofu S, Sherif B, Jugl S. Relationship between improvements in fatigue and signs & symptoms of active psoriatic: arthritis a sub-analysis of a phase 3 study with secukinumab. Poster presented at the 2015 ACR/ARHP Annual Meeting; November 10, 2015. San Francisco, CA. [abstract] Arthritis Rheumatol. 2015 Sep 29; 67(Suppl 10).
Hunter JE, Zepp JM, Gilmore MJ, Davis JV, Esterberg EJ, Muessig KR, Peterson SK, Syngal S, Acheson LS, Wiesner GL, Reiss JA, Goddard KA. Universal tumor screening for Lynch syndrome: assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers. Cancer. 2015 Sep 15;121(18):3281-9. doi: 10.1002/cncr.29470
Burris HA, Lebrun F, Rugo HS, Beck T, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci J-F, Bauly H, Taran T, Sahmoud T, Noguchi S. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer. 2013 Mar 15;119(10):1908-15.
Maurel J, Martins AS, Poveda A, Lopez-Guerrero JA, Cubedo R, Casado A, Martinez-Trufero J, Ramon Ayuso J, Lopez-Pousa A, Garcia-Albeniz X, Garcia del Muro X, de Alava E. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas. Cancer. 2010 Aug 1;116(15):3692-701. doi: 10.1002/cncr.25111
Helliwell PS, Doward L, Whalley D, Tennant A, McKenna S, Reynolds S, Kay L, Spoorenberg A, van der Heijde Leeds D. Psychometric and scaling properties of a new quality of life instrument specific to ankylosing spondylitis (AS). Poster presented at the 1999 ACR/ARHP Annual Scientific Meeting; November 14, 1999. Boston, MA. [abstract] Arthritis Rheumatol. 1999 Sep; 42(S9):s72.